Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR.

Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.

2.

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR.

Schizophr Bull. 2005 Jan;31(1):5-19. Epub 2005 Feb 16.

3.

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.

PMID:
18172019
4.

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):221-8. doi: 10.1176/appi.ajp.2007.07010089. Epub 2008 Jan 2.

PMID:
18172017
5.

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):214-20. doi: 10.1176/appi.ajp.2007.07010043. Epub 2008 Jan 2.

PMID:
18172018
6.

Drug initiatives to improve cognitive function.

Marder SR.

J Clin Psychiatry. 2006;67 Suppl 9:31-5; discussion 36-42.

7.

The MATRICS consensus cognitive battery: what we know 6 years later.

Green MF, Harris JG, Nuechterlein KH.

Am J Psychiatry. 2014 Nov 1;171(11):1151-4. doi: 10.1176/appi.ajp.2014.14070936. No abstract available.

PMID:
25756630
8.

[Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].

Rodríguez-Jiménez R, Bagney A, Moreno-Ortega M, García-Navarro C, Aparicio AI, López-Antón R, de la Oliva J, Jiménez-Arriero MÁ, Santos JL, Lobo A, Palomo T.

Rev Neurol. 2012 Nov 1;55(9):549-55. Review. Spanish.

9.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR.

Biol Psychiatry. 2004 Sep 1;56(5):301-7. Review.

PMID:
15336511
11.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A.

Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31.

PMID:
21075600
12.

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M.

Schizophr Bull. 2013 Mar;39(2):417-35. doi: 10.1093/schbul/sbr153. Epub 2011 Nov 22. Review.

13.

[MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].

Jedrasik-Styła M, Ciołkiewicz A, Denisiuk M, Linke M, Parnowska D, Gruszka A, Jarema M, Wichniak A.

Psychiatr Pol. 2012 Mar-Apr;46(2):261-71. Polish.

PMID:
23214396
14.

Measurement and Treatment Research toImprove Cognition in Schizophrenia Consensus Cognitive Battery: validation of the Japanese version.

Kaneda Y, Ohmori T, Okahisa Y, Sumiyoshi T, Pu S, Ueoka Y, Takaki M, Nakagome K, Sora I.

Psychiatry Clin Neurosci. 2013 Apr;67(3):182-8. doi: 10.1111/pcn.12029.

15.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
16.

Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.

Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS.

Schizophr Bull. 2011 Sep;37(5):1057-65. doi: 10.1093/schbul/sbq010. Epub 2010 Mar 1.

17.
18.

The NIMH-MATRICS consensus statement on negative symptoms.

Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR.

Schizophr Bull. 2006 Apr;32(2):214-9. Epub 2006 Feb 15. No abstract available.

19.

Stimulating the development of drug treatments to improve cognition in schizophrenia.

Green MF.

Annu Rev Clin Psychol. 2007;3:159-80. Review.

PMID:
17716052
20.

New paradigms for treatment development.

Stover EL, Brady L, Marder SR.

Schizophr Bull. 2007 Sep;33(5):1093-9. Epub 2007 Aug 2.

Items per page

Supplemental Content

Write to the Help Desk